Carglumic Acid Market - By Application: NAGS Deficiency, Hyperammonemia Management in Organic Acidemias, Other Urea Cycle Disorders (off-label); By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies; By Region: North America, Europe, Asia-Pacific Latin America and Others
1 | Market Overview
The global carglumic acid market is experiencing steady growth, driven by the increasing prevalence of hyperammonemia disorders and greater awareness of orphan diseases. Carglumic acid is mainly used to treat N-acetylglutamate synthase (NAGS) deficiency, a rare urea cycle disorder that causes excessive ammonia buildup in the blood.
The market is benefiting from improved newborn screening programs, better diagnostic capabilities, and expanding healthcare infrastructure in emerging economies. Supportive regulatory pathways for orphan drugs and increased R&D investments are further speeding up market adoption.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
0.42 |
Historical benchmark |
|
2024 |
0.61 |
Five-year CAGR 7.8% |
|
2031 |
1.19 |
Seven-year CAGR 9.7% |
The market is projected to almost double by 2031, driven by increased access to genetic testing and growing demand for rare disease treatments.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The carglumic acid market is highly consolidated, mainly controlled by one major player with worldwide regulatory approvals.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Product |
|
Recordati Rare Diseases |
87% |
Carbaglu® (carglumic acid) |
|
Others (Compounding Pharmacies, Generics in Development) |
13% |
Pipeline and early market entrants |
6 | Market Segmentation
By Application:
By Distribution Channel:
By Region:
7 | Strategic Outlook
Future growth will depend on label expansion, the availability of generics, and collaborative research in metabolic genetics. Emerging markets will be crucial as newborn screening and diagnostic networks grow
Need help?
Chat with our team in a minute.